US20130165652A1 - Novel heterocyclic compound, and composition for treating inflammatory diseases using same - Google Patents
Novel heterocyclic compound, and composition for treating inflammatory diseases using same Download PDFInfo
- Publication number
- US20130165652A1 US20130165652A1 US13/818,420 US201113818420A US2013165652A1 US 20130165652 A1 US20130165652 A1 US 20130165652A1 US 201113818420 A US201113818420 A US 201113818420A US 2013165652 A1 US2013165652 A1 US 2013165652A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- membered
- chemical formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(C)CC(=O)N1CCN(C(=O)CCCCCN)CC1.[1*]N([2*])C(=O)C1=NN2C([3*])=CC(C3=CC=CC=C3)=NC2=C1.[4*]C.[5*]C Chemical compound CC(C)CC(=O)N1CCN(C(=O)CCCCCN)CC1.[1*]N([2*])C(=O)C1=NN2C([3*])=CC(C3=CC=CC=C3)=NC2=C1.[4*]C.[5*]C 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N CC(C)=O Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- GGZYGLQDFSIANV-ITXCXOHRSA-N C/C=C/CC(O)C1=CN=C2C=CC(C(=O)N3CCCCC3)=CN12.CC1=CC(C)=CC(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=C1.CC1=CC(C2=CN=C3C(C)=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.CC1=CC(C2=CN=C3C=C(C(=O)N4CCCCC4)C=CN23)=CC=C1.CC1=CC(CC2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.CC1=CC=C(C)C(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=C1.CC1=CC=C(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)C=C1C.Cl Chemical compound C/C=C/CC(O)C1=CN=C2C=CC(C(=O)N3CCCCC3)=CN12.CC1=CC(C)=CC(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=C1.CC1=CC(C2=CN=C3C(C)=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.CC1=CC(C2=CN=C3C=C(C(=O)N4CCCCC4)C=CN23)=CC=C1.CC1=CC(CC2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.CC1=CC=C(C)C(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=C1.CC1=CC=C(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)C=C1C.Cl GGZYGLQDFSIANV-ITXCXOHRSA-N 0.000 description 2
- VZGISSJPQMADOT-UHFFFAOYSA-N CC(=O)CCC1=CN2C(=NC(C)=C2C2=CC=CC(C)=C2)C=C1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)CC3CCN(C(=O)OCC4=CC=CC=C4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCC(C)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCC(O)(C4CCCCC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)CN)CC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(CN4CCCCC4=O)=CN32)=CC=C1 Chemical compound CC(=O)CCC1=CN2C(=NC(C)=C2C2=CC=CC(C)=C2)C=C1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)CC3CCN(C(=O)OCC4=CC=CC=C4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCC(C)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCC(O)(C4CCCCC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)CN)CC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(CN4CCCCC4=O)=CN32)=CC=C1 VZGISSJPQMADOT-UHFFFAOYSA-N 0.000 description 2
- VNNWVEGAVWXNTJ-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)C2=CN3C(=NC(C)=C3C3=CC=CC=C3)C=C2)CC1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4=CC=CC=C4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4CC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(S(=O)(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(NC(=O)C3CCCCC3)C=CC2=N1 Chemical compound CC(=O)N1CCN(C(=O)C2=CN3C(=NC(C)=C3C3=CC=CC=C3)C=C2)CC1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4=CC=CC=C4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4CC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(S(=O)(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(NC(=O)C3CCCCC3)C=CC2=N1 VNNWVEGAVWXNTJ-UHFFFAOYSA-N 0.000 description 2
- QHDNPLGSUAWKNT-UHFFFAOYSA-N CC(=O)N1CCN(C2=CC(C3=C(C)N=C4C=CC(C(=O)N5CCCCC5)=CN43)=CC=C2)CC1.CC1=C(C2=CC=C(C3=CC=CC=C3)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=C3OCOC3=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(C(=O)CC(C)C)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(N3CCCCC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(N3CCOCC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1 Chemical compound CC(=O)N1CCN(C2=CC(C3=C(C)N=C4C=CC(C(=O)N5CCCCC5)=CN43)=CC=C2)CC1.CC1=C(C2=CC=C(C3=CC=CC=C3)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=C3OCOC3=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(C(=O)CC(C)C)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(N3CCCCC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(N3CCOCC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1 QHDNPLGSUAWKNT-UHFFFAOYSA-N 0.000 description 2
- BJMRZFKCLMRLTB-UHFFFAOYSA-N CC(=O)NC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=C(C2=CC=CC(O)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(OC(C)C)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC=C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)C=C1.CCOC(=O)C1=CC=C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)C=C1.COC1=CC=C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)C=C1 Chemical compound CC(=O)NC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=C(C2=CC=CC(O)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(OC(C)C)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC=C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)C=C1.CCOC(=O)C1=CC=C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)C=C1.COC1=CC=C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)C=C1 BJMRZFKCLMRLTB-UHFFFAOYSA-N 0.000 description 2
- PTQDZIXIDOOQHF-UHFFFAOYSA-N CC1=C(Br)N2C=C(C(=O)N3CCCCC3)N=C2C=C1.CC1=C(C)N2C=C(C(=O)N3CCCCC3)N=C2C=C1.CC1=C(Cl)N2C=C(C(=O)N3CCCCC3)N=C2C=C1.CC1=CC(Br)=CN2C=C(C(=O)N3CCCCC3)N=C12.CC1=CC=CC2=NC(C(=O)N3CCCCC3)=CN12.CC1=CN2C=C(C(=O)N3CCCCC3)N=C2C(C)=C1.CCN(CC)C(=O)C1=CN2C(=NC(C)=C2C2=CC=CC=C2)C=C1.O=C(C1=CN2C=C(Br)C=CC2=N1)N1CCCCC1 Chemical compound CC1=C(Br)N2C=C(C(=O)N3CCCCC3)N=C2C=C1.CC1=C(C)N2C=C(C(=O)N3CCCCC3)N=C2C=C1.CC1=C(Cl)N2C=C(C(=O)N3CCCCC3)N=C2C=C1.CC1=CC(Br)=CN2C=C(C(=O)N3CCCCC3)N=C12.CC1=CC=CC2=NC(C(=O)N3CCCCC3)=CN12.CC1=CN2C=C(C(=O)N3CCCCC3)N=C2C(C)=C1.CCN(CC)C(=O)C1=CN2C(=NC(C)=C2C2=CC=CC=C2)C=C1.O=C(C1=CN2C=C(Br)C=CC2=N1)N1CCCCC1 PTQDZIXIDOOQHF-UHFFFAOYSA-N 0.000 description 2
- QLNCPNQEFHIVOB-UHFFFAOYSA-N CC1=C(C(=O)N2CCCCC2)N2C=C(Br)C=CC2=N1.CC1=C(C(=O)N2CCCCC2)N2C=C(C3=CC=C(Cl)C=C3)C=CC2=N1.CC1=C(C2=CC=C(Cl)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=C(F)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(Cl)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=CC(CC2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC=C(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)C=C1 Chemical compound CC1=C(C(=O)N2CCCCC2)N2C=C(Br)C=CC2=N1.CC1=C(C(=O)N2CCCCC2)N2C=C(C3=CC=C(Cl)C=C3)C=CC2=N1.CC1=C(C2=CC=C(Cl)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=C(F)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(Cl)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=CC(CC2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC=C(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)C=C1 QLNCPNQEFHIVOB-UHFFFAOYSA-N 0.000 description 2
- ILBTUIROIZZKJK-UHFFFAOYSA-N CC1=C(C2=CC=C(N)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(C(C)C)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(NS(C)(=O)=O)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=CC(C)=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=C1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCC4)=CN32)=CC=C1.CC1=CC=C(C)C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=C1.COC1=CC(C2=C(C)[N+](C)=C3C=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.[I-] Chemical compound CC1=C(C2=CC=C(N)C=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(C(C)C)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(NS(C)(=O)=O)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=CC(C)=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=C1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCC4)=CN32)=CC=C1.CC1=CC=C(C)C(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=C1.COC1=CC(C2=C(C)[N+](C)=C3C=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.[I-] ILBTUIROIZZKJK-UHFFFAOYSA-N 0.000 description 2
- BLFJBEHSCZRAMB-UHFFFAOYSA-N CC1=C(C2=CC=CC(C(C)C)=C2)N2C=C(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCN(C(=O)C5CCCCC5)CC4)=CN32)=CC=C1 Chemical compound CC1=C(C2=CC=CC(C(C)C)=C2)N2C=C(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCN(C(=O)C5CCCCC5)CC4)=CN32)=CC=C1 BLFJBEHSCZRAMB-UHFFFAOYSA-N 0.000 description 2
- ANHOZTBJHXYVSZ-UHFFFAOYSA-N CC1=C(C2=CC=CC(N3CCN(C(=O)C4CCCCC4)CC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(OCC3CCCCC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(NC(=O)C3CCOCC3)C=CC2=N1.CC1=CC(C(=O)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC(C(C)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC(C(O)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC(C(OCC2CCCCC2)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1 Chemical compound CC1=C(C2=CC=CC(N3CCN(C(=O)C4CCCCC4)CC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC(OCC3CCCCC3)=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(NC(=O)C3CCOCC3)C=CC2=N1.CC1=CC(C(=O)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC(C(C)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC(C(O)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1.CC1=CC(C(OCC2CCCCC2)C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1 ANHOZTBJHXYVSZ-UHFFFAOYSA-N 0.000 description 2
- FRCBVXOGEYUPHF-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=CC(C(=O)N3CCCCC3)=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=CC=C(C(=O)N3CCCCC3)C2=N1.CC1=C(C2=CC=CC=C2)N=C2C=CC(C(=O)N3CCCCC3)=CN21.CC1=C(N)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CCN(CC)C(=O)C1=C(C)N=C2C=CC(Br)=CN21.NC1=C(C2=CC=CC=C2)N=C2C=CC(C(=O)N3CCCCC3)=CN21.O=C(C1=C(Br)N2C=C(Br)C=CC2=N1)N1CCCCC1 Chemical compound CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=CC(C(=O)N3CCCCC3)=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=CC=C(C(=O)N3CCCCC3)C2=N1.CC1=C(C2=CC=CC=C2)N=C2C=CC(C(=O)N3CCCCC3)=CN21.CC1=C(N)N2C=C(C(=O)N3CCCCC3)C=CC2=N1.CCN(CC)C(=O)C1=C(C)N=C2C=CC(Br)=CN21.NC1=C(C2=CC=CC=C2)N=C2C=CC(C(=O)N3CCCCC3)=CN21.O=C(C1=C(Br)N2C=C(Br)C=CC2=N1)N1CCCCC1 FRCBVXOGEYUPHF-UHFFFAOYSA-N 0.000 description 2
- BFEMEPHEZGAERF-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)(=O)C4=CC=CS4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4=NC=CC=C4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)CC4CCCCC4)CC3)C=CC2=N1.CC1=CC=C(CC(=O)N2CCN(C(=O)C3=CN4C(=NC(C)=C4C4=CC=CC=C4)C=C3)CC2)C=C1.CCC1(O)CCN(C(=O)C2=CN3C(=NC(C)=C3C3=CC=CC=C3)C=C2)CC1.[H]C(O)(C1CCCCC1)C1CCN(C(=O)C2=CN3C(=NC(C)=C3C3=CC=CC=C3)C=C2)CC1 Chemical compound CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)(=O)C4=CC=CS4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4=NC=CC=C4)CC3)C=CC2=N1.CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)CC4CCCCC4)CC3)C=CC2=N1.CC1=CC=C(CC(=O)N2CCN(C(=O)C3=CN4C(=NC(C)=C4C4=CC=CC=C4)C=C3)CC2)C=C1.CCC1(O)CCN(C(=O)C2=CN3C(=NC(C)=C3C3=CC=CC=C3)C=C2)CC1.[H]C(O)(C1CCCCC1)C1CCN(C(=O)C2=CN3C(=NC(C)=C3C3=CC=CC=C3)C=C2)CC1 BFEMEPHEZGAERF-UHFFFAOYSA-N 0.000 description 2
- LGXMNMDHFUPUDX-UHFFFAOYSA-N CC1=CC(C)=C(Br)N2C=C(C(=O)N3CCCCC3)N=C12.CC1=CC2=NC(C(=O)N3CCCCC3)=CN2C(C)=C1.CC1=CC=C(C2=CN3C=C(C(=O)N4CCCCC4)N=C3C(C)=C2)C=C1.O=C(C1=CN2C(=NC(C3CC3)=C2C2=CC=C(Cl)C=C2)C=C1)N1CCCCC1.O=C(C1=CN2C(=NC(C3CC3)=C2C2=CC=C(N3CCOCC3)C=C2)C=C1)N1CCCCC1.O=C(C1=CN2C(C(O)C3=CC=CC=C3)=CN=C2C=C1)N1CCCCC1.O=C(C1=CN2C(C3=CC=C(Cl)C=C3)=CN=C2C=C1)N1CCCCC1 Chemical compound CC1=CC(C)=C(Br)N2C=C(C(=O)N3CCCCC3)N=C12.CC1=CC2=NC(C(=O)N3CCCCC3)=CN2C(C)=C1.CC1=CC=C(C2=CN3C=C(C(=O)N4CCCCC4)N=C3C(C)=C2)C=C1.O=C(C1=CN2C(=NC(C3CC3)=C2C2=CC=C(Cl)C=C2)C=C1)N1CCCCC1.O=C(C1=CN2C(=NC(C3CC3)=C2C2=CC=C(N3CCOCC3)C=C2)C=C1)N1CCCCC1.O=C(C1=CN2C(C(O)C3=CC=CC=C3)=CN=C2C=C1)N1CCCCC1.O=C(C1=CN2C(C3=CC=C(Cl)C=C3)=CN=C2C=C1)N1CCCCC1 LGXMNMDHFUPUDX-UHFFFAOYSA-N 0.000 description 2
- HDBYKLJEHZKQSJ-UHFFFAOYSA-N CC1=CC(C2=CN=C3C=CC(C(=O)N4CCCC4)=CN23)=CC=C1.CC1=CC(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.CC1=CC=CC=C1C1=CN=C2C=CC(C(=O)N3CCCCC3)=CN12.CC1=CN2C(C(=O)N3CCCCC3)=CN=C2C=C1.O=C(C1=CN2C(C3=CC=CC=C3)=CN=C2C=C1)N1CCN(C(=O)C2CCCCC2)CC1.O=C(C1=CN2C(CC3=CC=CC=C3)=CN=C2C=C1)N1CCCCC1.O=C(C1=CN=C2C=CC(Br)=CN12)N1CCCCC1 Chemical compound CC1=CC(C2=CN=C3C=CC(C(=O)N4CCCC4)=CN23)=CC=C1.CC1=CC(C2=CN=C3C=CC(C(=O)N4CCCCC4)=CN23)=CC=C1.CC1=CC=CC=C1C1=CN=C2C=CC(C(=O)N3CCCCC3)=CN12.CC1=CN2C(C(=O)N3CCCCC3)=CN=C2C=C1.O=C(C1=CN2C(C3=CC=CC=C3)=CN=C2C=C1)N1CCN(C(=O)C2CCCCC2)CC1.O=C(C1=CN2C(CC3=CC=CC=C3)=CN=C2C=C1)N1CCCCC1.O=C(C1=CN=C2C=CC(Br)=CN12)N1CCCCC1 HDBYKLJEHZKQSJ-UHFFFAOYSA-N 0.000 description 2
- NQUIZXMDMBDODK-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1 Chemical compound CC1=C(C2=CC=CC=C2)N2C=C(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C=CC2=N1.CC1=CC(C2=C(C)N=C3C=CC(C(=O)N4CCCCC4)=CN32)=CC=C1 NQUIZXMDMBDODK-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a protease activated receptor-2 (PAR-2) inhibitor and a composition for treating and preventing an inflammatory disease, as compounds containing imidazopyridine derivatives, which are novel heterocyclic compounds, and salts thereof.
- PAR-2 protease activated receptor-2
- Protease activated receptor-2 which is a receptor belonging to a G-protein-coupled receptor (GPCR), is a receptor found in association with a thrombin receptor (PAR-1) discovered in 1991.
- GPCR G-protein-coupled receptor
- PAR-2 has a specific activation mechanism in that PAR-2 is activated as a peptide sequence (SLIGRL in human) exhibited in a receptor terminal is bonded to a specific site of the PAR-2 while protease such as trypsin or mast cell-derived tryptase decomposes a specific site of peptide sequences present in a terminal of an extracellular domain of the PAR-2 (Exp. Rev. Mol. Med., 4(16), 1-17, 2002).
- the PAR-2 plays important roles in inflammatory response of skin, a skin barrier function, generation of pruritus, or the like, relationship between the role of the PAR-2 and atopic dermatitis having the above-mentioned symptoms as main symptoms has been strongly suggested. It was known that the PAR-2 is expressed in various cells of human, and particularly, it was reported that the PAR-2 induces an inflammatory response and an activation reaction of nerve cells, or the like. In addition, it was reported that since the PAR-2 stimulates movement of melanosome while being involved in a signal transmission mechanism between kerationocyte and melanocyte in the skin, the PAR-2 is closely associated with skin pigmentation (Drug Dev. Res., 59, 408-416, 2003).
- the present inventors synthesized various materials and confirmed the activity thereof over a long time in order to synthesize a material having PAR-2 inhibitory activity. As a result, the present inventors developed a novel compound having excellent PAR-2 inhibitory activity.
- An object of the present invention is to provide imidazopyridine compounds represented by the following Chemical Formula 1, as a novel heterocyclic compound.
- Another object of the present invention is to provide a pharmaceutical composition containing compounds of Chemical Formula 1, which are the heterocyclic compounds according to the present invention, and pharmaceutically acceptable salts thereof, for treating or preventing an inflammatory disease, and provide a protease activated receptor-2 (PAR-2) inhibitor composition containing the compounds of Chemical Formula 1 or pharmaceutically acceptable salts thereof.
- PAR-2 protease activated receptor-2
- imidazopyridine compounds represented by the following Chemical Formula 1, which are novel heterocyclic compounds.
- R 1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, (C6-C12)ar(C1-C7)alkyl, and
- R 2 and R 3 each are independently selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C3-C6)cycloalkyl, (C6-C10)aryl, (C6-C10)ar(C1-C7)alkyl, (C1-C7)alkylamido(C1-C7)alkyl, —NR 11 R 12 ,
- R 11 , R 12 , R 13 , R 14 , and R 15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl;
- R 11 and R 12 , and R 13 and R 14 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form 5- or 6-membered heterocyclic ring;
- R 16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
- n is an integer of 1 to 4.
- (C6-C12)aryl of R 2 and R 3 and heterocyclic ring formed from; R 11 and R 12 , and R 13 and R 14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsul
- R 21 and R 22 each may be independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R 21 and R 22 may be linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.
- alkyl in the present invention, the terms “alkyl”, “alkoxy” and other substituents including an “alkyl” part may include both of the straight chain type and the branched chain type.
- (C1-C7) alkyl includes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, n-hexyl, and n-heptyl;
- C1-C6)alkoxy includes methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, n-penthoxy i-penthoxy, and n-hexyloxy;
- (C3-C6)cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl
- heterocycloalkyl that is, aliphatic heterocyclic ring may include morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolidonyl, piperidonyl, oxazolidinonyl, thiazolidinoyl;
- heteroaryl includes monocyclic heteroaryl such as furyl, thiophenyl, pyrrolyl, pyranyl, imidazolyl, pyrazolyl, triazolyl, thiadiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, furazanyl, pyridyl, pyrazinyl,
- the compound of Chemical Formula 1, which is the heterocyclic compound according to the present invention may include imidazopyridine compounds represented by the following Chemical Formula 2.
- R 1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, and
- R 2 is independently selected from hydrogen, halogen, amino, (C1-C7)alkyl, (C6-10)aryl, —NR 11 R 12 ,
- R 4 may be selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C6-C10)aryl, (C1-C7)alkylamido(C1-C7)alkyl, —NR 11 R 12 ,
- R 11 , R 12 , R 13 , R 14 , and R 15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl;
- R 11 and R 12 , and R 13 and R 14 may be bonded to alkylene, oxyalkylene, or aminoalkylene to form a 5- or 6-membered heterocyclic ring;
- R 16 may be selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
- (C6-C12)aryl of R 2 and R 4 and heterocyclic ring formed from R 11 and R 12 , and R 13 and R 14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulf
- R 21 and R 22 each may be independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R 21 and R 22 may be linked to each other via alkylene to form 5- or 6-membered heterocyclic ring;
- R 5 may be independently selected from halogen and (C1-C7)alkyl
- n is an integer of 1 to 3.
- the compound of Chemical Formula 1, which is the heterocyclic compound according to the present invention may include imidazopyridine compounds represented by the following Chemical Formula 3.
- R 1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, and
- R 2 is independently selected from hydrogen, halogen, amino, (C1-C7)alkyl, (C6-10)aryl, —NR 11 R 12 ,
- R 6 is —NR 11 R 12 ;
- R 11 and R 12 each independently may be hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, heteroaryl, and R 11 and R 12 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- or 6-membered heterocyclic ring;
- R 16 may be selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)ary; and
- (C6-C12)aryl of R 2 and R 6 and heterocyclic ring formed from R 11 and R 12 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1
- R 21 and R 22 each may be independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R 21 and R 22 may be linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.
- the compound of Chemical Formula 1, which is the heterocyclic compound according to the present invention may include imidazopyridine compounds represented by the following Chemical Formula 4.
- R 2 is amino, (C6-C10)aryl, or (C6-C10)ar(C1-C7)alkyl;
- A is —CH 2 or —NR 31 ;
- R 31 may be selected from hydrogen, (C1-C7)alkyl, (C1-C7)alkylcarbonyl, and (C3-C6)cycloalkylcarbonyl; aryl and arylalkyl of R 2 may be further substituted with halogen, hydroxy, amino, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, 5- or 6-membered heterocycloalkyl, or 5- or 6-membered heteroaryl.]
- the hetero compound represented by Chemical Formula 1 according to the present invention may be selected from compounds of the following structures, but is not limited thereto.
- a pharmaceutical composition for treating and preventing inflammatory skin diseases containing a heterocyclic compound of Chemical Formula 1 according to the present invention or pharmaceutically acceptable salts thereof.
- the inflammatory skin disease may include a skin disease with inflammation and may include acne, rosacea, seborrheic dermatitis, atopic dermatitis, post-inflammatory hyper-pigmentation (PIH), contact dermatitis, pruritus, psoriasis, Lichen planus, eczema, skin infections, Netherton Syndrome, or the like.
- PHI post-inflammatory hyper-pigmentation
- composition for skin wound healing containing a heterocyclic compound of Chemical Formula 1 according to the present invention or pharmaceutically acceptable salts thereof.
- the skin wound may include a cut, a stab, an abrasion, a laceration, a bite wound, or the like, but is not limited thereto.
- a pharmaceutical composition for treating and preventing metastasis of cancer, gastrointestinal disease, asthma, or hepatic cirrhosis containing a heterocyclic compound of Chemical Formula 1 or pharmaceutically acceptable salts thereof according to the present invention.
- protease activated receptor-2 (PAR-2) inhibitor composition containing a heterocyclic compound of Chemical Formula 1 according to the present invention or pharmaceutically acceptable salts thereof.
- a compound of Chemical Formula 1, or salts thereof according to the present invention may have a PAR-2 inhibitory activity. It is known that the PAR-2 plays important roles mainly in diseases such as inflammation, cardiovascular diseases, cancer, particularly, metastasis of cancer, gastrointestinal disease such as inflammatory bowel disease (IBD), and the like, asthma, hepatic cirrhosis, or the like. Since the diseases in association with PAR-2 are mostly intractable chronic diseases as described above, the development of an effective PAR-2 inhibitor may be expected to have a large commercial potential.
- diseases in association with PAR-2 are mostly intractable chronic diseases as described above, the development of an effective PAR-2 inhibitor may be expected to have a large commercial potential.
- the PAR-2 is involved in an important response such as intracellular hyper-pigmentation, induction of pruritus, and the like, as well as inflammation.
- the PAR-2 plays important roles in maintenance of a skin barrier function, wound healing, and the like. Therefore, the PAR-2 inhibitor is likely to effectively treat skin diseases.
- atopic dermatitis in which various skin symptoms are shown at the same time, since in the atopic dermatitis, which is an intractable chronic inflammatory skin disease, various symptoms such as severe pruritus, skin barrier damage, inflammation post-inflammatory hyper-pigmentation (PIH), and the like, that may be expressed by activation of PAR-2 are shown at the same time, the PAR-2 inhibitor may be primarily applied to the atopic disease.
- the compounds of Chemical Formula 1 or salts thereof according to the present invention may be used in order to heal skin wounds as well as to treat and prevent inflammatory diseases such as skin inflammation, atopic dermatitis, or the like and be useful as medicine or a cosmetic composition.
- the compound of Chemical Formula 1 and salts thereof according to the present invention may be useful as the PAR-2 inhibitory activity.
- FIGS. 1 and 2 are profiles of a PAR-2 inhibitory activity assay specified in Experimental Example 1;
- FIGS. 3 and 4 are results of ⁇ -arrestin assay in Experimental Example 2;
- FIG. 5 is a graph showing an effect of recovering trans-epidermal water loss (TEWL) in oxazolone induced chronic dermatitis animal model
- FIG. 6 is a graph showing an effect of recovering skin hydration in stratum cornea in the oxazolone induced chronic dermatitis animal model.
- FIG. 7 is a graph showing an effect of decreasing a skin thickness in the oxazolone induced chronic dermatitis animal model.
- the present invention provides imidazopyridine compounds represented by the following Chemical Formula 1, which are novel heterocyclic compounds.
- R 1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, (C6-C12)ar(C1-C7)alkyl, and
- R 2 and R 3 each are independently selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C3-C6)cycloalkyl, (C6-C10)aryl, (C6-C10)ar(C1-C7)alkyl, (C1-C7)alkylamido(C1-C7)alkyl, —NR 11 R 12 ,
- R 11 , R 12 , R 13 , R 14 , and R 15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl;
- R 11 and R 12 , and R 13 and R 14 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- to 6-membered heterocyclic ring;
- R 16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
- n 1 to 4
- (C6-C12)aryl of R 2 and R 3 and heterocyclic ring formed from R 11 and R 12 , and R 13 and R 14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulf
- R 21 and R 22 each are independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R 21 and R 22 are linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.
- preferable heterocyclic compounds are imidazopyridine compounds represented by the following Chemical Formulas 1a and 1b among imidazopyridine derivative compounds represented by Chemical Formula 1.
- the present invention provides the pharmaceutical composition for treating or preventing the inflammatory skin diseases, the cosmetic composition, and the PAR-2 inhibitor composition containing the compounds of Chemical Formula 1 or pharmaceutically acceptable salts thereof, wherein the inflammatory skin diseases includes skin barrier damage, psoriasis with skin inflammation, Netherton Syndrome, and atopic dermatitis.
- the present invention may provide a composition for skin wound healing using the fact that inhibition of PAR-2 expression may stimulate wound healing.
- the composition or the PAR-inhibitor may include 0.001 to 90 weight %, more preferably, 0.001 to 50 weight % of the compounds of Chemical Formula 1 according to the present invention as an active ingredient.
- the pharmaceutical composition containing the compounds of Chemical Formula 1 or pharmaceutically acceptable salts thereof for treating or preventing the inflammatory skin diseases or for skin wound healing and the PAR-2 inhibitor composition according to the present invention may include all of the compositions that may be administered to a human for skin external application, injection, inhalation, oral administration, and the like.
- a formulation that may be applied to the skin or mucosa is not particularly limited, but the composition may be formulated as a solution, emulsion, suspension, cream, ointment, gel, jelly, or spray.
- the compound of Chemical Formula 1 according to the present invention may be prepared through the pathway of the following Reaction Formula 1.
- 6-aminonicotinic acid methylester 500 mg, 3.29 mmol
- chloroacetone 1.83 g, 19.74 mmol
- the resultant was diluted with water (15 mL), basified by sodium hydrogen carbonate saturated aqueous solution and then extracted three times with methylene chloride (MC, 10 mL).
- MC methylene chloride
- 3-iodo-2-methylimidazo[1,2-a]pyridine-6-carboxylic acid (202 mg, 85%) was obtained using the compound (250 mg, 0.791 mmol) obtained in step 2 by the same method as that in Preparation step 2 of Example 2. The obtained compound was directly used in a next reaction without purification.
- step 1 After the compound (80 mg, 0.30 mmol) obtained in step 1 was dissolved in a mixture of tetrahydrofuran (2 mL) and ethanol (2 mL), lithium hydroxide (20 mg, 0.48 mmol) was added thereto, and water (1 mL) was added thereto, followed by stirring for 12 hours. The resultant was neutralized with 1N HCl and concentrated under reduced pressure, thereby obtaining 2-methyl-3-phenylimidazo[1,2-a]pyridine-6-carboxylic acid (78 mg, 98%). The obtained compound was directly used in a next reaction without purification
- the PAR-2 is a kind of G-protein coupled receptors (GPCR), and when the PAR-2 is activated in cell, phospholipase C-b (PLC-b) decomposes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacyl glycerol (DAG) while being activated.
- GPCR G-protein coupled receptors
- IP3 generated at this time stimulates secretion of calcium ions in endoplasmic reticulum (ER), which is a storage of calcium ions in a cell, such that the concentration of calcium ions in the cell is increased.
- ER endoplasmic reticulum
- an in vitro screening assay system capable of detecting a material capable of suppressing the concentration of calcium ions in the cell from being increased by activation of PAR-2 was constructed.
- activating peptide (AP) was used, and as a reagent for detecting the concentration of calcium ion in the cell, a Calcium-4 assay kit produced (Molecular Probe).
- AP activating peptide
- a Calcium-4 assay kit produced (Molecular Probe).
- HCT-15 As a cell line used in experiments, HCT-15 in which PAR-2 is over-expressed was used. Inhibitor candidates were treated for 5 minutes and then treated with AP, a change in fluorescence was observed for 2 minutes in real time using a FlexStation II (Molecular Device Corp.).
- the inhibitory activity of the synthesized materials against the PAR-2 was evaluated using the protocol as described above, and profiles of the assay for Compounds 45 and 73 prepared in Examples 1 and 2 were shown in FIGS. 1 and 2 .
- An in vitro assay protocol capable of detecting activation of the PAR-2 was additionally introduced in addition to a calcium immobilization assay to measure the activity of the selected materials.
- the PAR-2 inhibitory activities of two kinds of samples were measured using a PathHunterTM ⁇ -arrestin GPCR assay kit (DiscoveRx Corp.) capable of detecting accumulation of ⁇ -arrestin, which is an intracellular reaction firstly generated by the activation of the PAR-2.
- ⁇ -arrestin which is an intracellular reaction firstly generated by the activation of the PAR-2.
- Experiments were conducted by diluting concentrations of the samples by one-half, ranging from 1000 to 50 ⁇ M and SKIGKV-NH2 (10 ⁇ M) was treated with the PAR-2 inhibitor.
- suppression of ⁇ -arrestin was confirmed in both of the two kinds of samples at a concentration of 500 ⁇ M.
- a cell line having the following structure was prepared based on existing references, and activation of the PAR-2 was observed using a confocal microscope.
- As the cell line Kirsten Murine Sarcoma Virus transformed rat kidney epithelial cell (KNRK cell) was used. In this cell line, the PAR-2 may not be expressed in a normal state.
- KNRK cell Kirsten Murine Sarcoma Virus transformed rat kidney epithelial cell
- the PAR-2 may not be expressed in a normal state.
- Each of the N-terminals of KNRK cell were tagged with Flag epitope, and each of the C-terminals were tagged with Myc epitope, such that a stable transfected cell was constructed.
- 0.05% desonide formulation which is a steroid having relatively weak potency, was used, and changes in trans-epidermal water loss (TEWL) skin hydration in stratum cornea, and skin thickness were observed.
- TEWL trans-epidermal water loss
- FIGS. 5 to 7 it was observed that Compound 45 may effectively restore trans-epidermal water loss (TEWL) and skin hydration in stratum cornea and reduce the skin thickness.
- Compound 45 has statistically significant improvement effect on the skin thickness.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The heterocyclic compound according to the present invention may treat and prevent inflammatory diseases and heal skin wounds, and particularly, have effects of recovering damaged skin barrier, reducing inflammation and pruritus in inflammatory skin diseases. In addition, the composition containing the compound according to the present invention as an active ingredient may be used to alleviate various inflammatory diseases and diseases in which PAR-2 is excessively expressed, and particularly, the composition may inhibit activity of PAR-2 in skin, such that the composition may be used as a composition having anti-inflammatory function in inflammatory skin diseases including atopic dermatitis, or the like.
Description
- The present invention relates to a protease activated receptor-2 (PAR-2) inhibitor and a composition for treating and preventing an inflammatory disease, as compounds containing imidazopyridine derivatives, which are novel heterocyclic compounds, and salts thereof.
- Protease activated receptor-2 (PAR-2), which is a receptor belonging to a G-protein-coupled receptor (GPCR), is a receptor found in association with a thrombin receptor (PAR-1) discovered in 1991. As a result of research into PAR-2 activation mechanism, it is known that the PAR-2 has a specific activation mechanism in that PAR-2 is activated as a peptide sequence (SLIGRL in human) exhibited in a receptor terminal is bonded to a specific site of the PAR-2 while protease such as trypsin or mast cell-derived tryptase decomposes a specific site of peptide sequences present in a terminal of an extracellular domain of the PAR-2 (Exp. Rev. Mol. Med., 4(16), 1-17, 2002).
- Recently, it is reported that the PAR-2 plays important roles in inflammatory response of skin, a skin barrier function, generation of pruritus, or the like, relationship between the role of the PAR-2 and atopic dermatitis having the above-mentioned symptoms as main symptoms has been strongly suggested. It was known that the PAR-2 is expressed in various cells of human, and particularly, it was reported that the PAR-2 induces an inflammatory response and an activation reaction of nerve cells, or the like. In addition, it was reported that since the PAR-2 stimulates movement of melanosome while being involved in a signal transmission mechanism between kerationocyte and melanocyte in the skin, the PAR-2 is closely associated with skin pigmentation (Drug Dev. Res., 59, 408-416, 2003).
- In addition, with regard to the skin barrier function, it was reported that activation of the PAR-2 is closely associated with the skin barrier function. That is, it was reported that when the skin barrier function is damaged, an activity of the protease in a stratum corneum is rapidly increased and thus the PAR-2 is activated (J. Invest. Dermatol., 126, 2074-2076, 2006), and it was confirmed that a material derived from dust mite or a cockroach, which is a kind of allergens inducing and exacerbating atopic dermatitis, also may activate the PAR-2. According to a prior study of the present inventors, in the case in which an allergen was applied on skin barrier-damaged skin of which a skin barrier was damaged, the recovery of the skin barrier function was hindered due to activation of the PAR-2 as described above, and in the case in which the allergen and a PAR-2 inhibitor were simultaneously applied, a barrier recovery mechanism was normalized (J. Invest. Dermatol., 128, 1930-1939, 2008). Further, it was reported that when the PAR-2 inhibitor is applied on the skin barrier-damaged skin, the recovery of the skin barrier is stimulated. It is expected that since damage of the skin barrier in the skin of the atopic dermatitis patient is the most general symptom, the recovery effect of the PAR-2 inhibitor from the skin barrier damage will assist in treating symptoms of atopic dermatitis.
- It was reported that when the PAR-2 is activated in the skin, pruritus is generated, and a behavior of scratching the skin is induced due to this pruritus. According to an existing study results on an anti-pruritus effect of the PAR-2 inhibitor (JP 2004-170323), it was reported that in the case in which the PAR-2 inhibitor is applied to the skin, scratching is significantly decreased. As a mechanism of pruritus, it is known that nerve cells are activated by activation of the PAR-2 present in nerve fibers in the skin, and then a pruritus signal is transmitted to a brain. A function of PAR-2 associated with pruritus was confirmed through the fact that in the case of applying a PAR-2 activating material to the skin of animal models, the number of scratching action was rapidly increased, and in the case of inhibiting the activity of PAR-2, this phenomenon was suppressed (J. Neurosci., 23, 6176-6180, 2003).
- As a material having a selective PAR-2 inhibitory effect, it is known that currently, two kinds are developed all over the word. Among them, a material of which the effect is verified through academic journals is an ENMD-1,068 produced by ENtreMed. Corp. which is a bio-venture company in the US. Further, a PAR-2 inhibitor produced by Sumitomo Pharma Co. is disclosed in Japanese Patent Laid-open Publication No. 2004-170323.
- Exacerbation of inflammation by the PAR-2 and an anti-inflammatory effect of a material having a PAR-2 inhibitory effect was confirmed through the fact that when trypsin, which is a protease activating PAR-2, or activating peptide (AP), which is an activating material of PAR-2, is applied to the skin, the inflammatory response is increased, and when the protease inhibitor is simultaneously applied, this inflammatory response is decreased (FASEB. J., 17, 1871-1885, 2003).
- The present inventors synthesized various materials and confirmed the activity thereof over a long time in order to synthesize a material having PAR-2 inhibitory activity. As a result, the present inventors developed a novel compound having excellent PAR-2 inhibitory activity.
- An object of the present invention is to provide imidazopyridine compounds represented by the following Chemical Formula 1, as a novel heterocyclic compound.
- Another object of the present invention is to provide a pharmaceutical composition containing compounds of Chemical Formula 1, which are the heterocyclic compounds according to the present invention, and pharmaceutically acceptable salts thereof, for treating or preventing an inflammatory disease, and provide a protease activated receptor-2 (PAR-2) inhibitor composition containing the compounds of Chemical Formula 1 or pharmaceutically acceptable salts thereof.
- In one general aspect, according to the present invention, there is provided imidazopyridine compounds represented by the following Chemical Formula 1, which are novel heterocyclic compounds.
- [In Chemical Formula 1,
- R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, (C6-C12)ar(C1-C7)alkyl, and
- R2 and R3 each are independently selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C3-C6)cycloalkyl, (C6-C10)aryl, (C6-C10)ar(C1-C7)alkyl, (C1-C7)alkylamido(C1-C7)alkyl, —NR11R12,
- R11, R12, R13, R14, and R15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl; R11 and R12, and R13 and R14 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form 5- or 6-membered heterocyclic ring; R16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
- m is an integer of 1 to 4; and
- (C6-C12)aryl of R2 and R3 and heterocyclic ring formed from; R11 and R12, and R13 and R14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino, (C1-C7)alkylamido, (C1-C7)alkylcarbamoyl, (C1-C7)alkylsulfonamido, or
- and R21 and R22 each may be independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 may be linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.]
- In the present invention, the terms “alkyl”, “alkoxy” and other substituents including an “alkyl” part may include both of the straight chain type and the branched chain type. In addition, (C1-C7) alkyl includes methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, n-hexyl, and n-heptyl; (C1-C6)alkoxy includes methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, n-penthoxy i-penthoxy, and n-hexyloxy; (C3-C6)cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; and (C6-C12)aryl includes phenyl, naphthyl, biphenyl, and anthryl. 5- or 6-membered heterocyclic ring may include both of the aliphatic heterocyclic ring and heteroaryl. Particularly, heterocycloalkyl, that is, aliphatic heterocyclic ring may include morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolidonyl, piperidonyl, oxazolidinonyl, thiazolidinoyl; heteroaryl includes monocyclic heteroaryl such as furyl, thiophenyl, pyrrolyl, pyranyl, imidazolyl, pyrazolyl, triazolyl, thiadiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, furazanyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, or the like, and polycyclic heteroaryl such as benzofuranyl, benzothiophenyl, isobenzofuranyl, benzimidazolyl, benzothiazolyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, isoindolyl, indolyl, indazolyl, benzothiadiazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinolizinyl, quinoxalinyl, carbazolyl, phenanthridinyl, benzodioxolyl, or the like.
- The compound of Chemical Formula 1, which is the heterocyclic compound according to the present invention, may include imidazopyridine compounds represented by the following Chemical Formula 2.
- R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, and
- R2 is independently selected from hydrogen, halogen, amino, (C1-C7)alkyl, (C6-10)aryl, —NR11R12,
- R4 may be selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C6-C10)aryl, (C1-C7)alkylamido(C1-C7)alkyl, —NR11R12,
- R11, R12, R13, R14, and R15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl; R11 and R12, and R13 and R14 may be bonded to alkylene, oxyalkylene, or aminoalkylene to form a 5- or 6-membered heterocyclic ring; R16 may be selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
- (C6-C12)aryl of R2 and R4 and heterocyclic ring formed from R11 and R12, and R13 and R14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino, (C1-C7)alkylamido, (C1-C7)alkylcarbamoyl, (C1-C7)alkylsulfonamido, or
- R21 and R22 each may be independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 may be linked to each other via alkylene to form 5- or 6-membered heterocyclic ring;
- R5 may be independently selected from halogen and (C1-C7)alkyl; and
- n is an integer of 1 to 3.]
- In addition, the compound of Chemical Formula 1, which is the heterocyclic compound according to the present invention, may include imidazopyridine compounds represented by the following Chemical Formula 3.
- [In
Chemical Formula 3, - R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, and
- R2 is independently selected from hydrogen, halogen, amino, (C1-C7)alkyl, (C6-10)aryl, —NR11R12,
- R6 is —NR11R12; R11 and R12 each independently may be hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, heteroaryl, and R11 and R12 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- or 6-membered heterocyclic ring; R16 may be selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)ary; and
- (C6-C12)aryl of R2 and R6 and heterocyclic ring formed from R11 and R12 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino, (C1-C7)alkylamido, (C1-C7)alkylcarbamoyl, (C1-C7)alkylsulfonamido, or
- R21 and R22 each may be independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 may be linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.]
- Preferably, the compound of
Chemical Formula 1, which is the heterocyclic compound according to the present invention, may include imidazopyridine compounds represented by the following Chemical Formula 4. - [In Chemical Formula 4,
- R2 is amino, (C6-C10)aryl, or (C6-C10)ar(C1-C7)alkyl;
- A is —CH2 or —NR31; R31 may be selected from hydrogen, (C1-C7)alkyl, (C1-C7)alkylcarbonyl, and (C3-C6)cycloalkylcarbonyl; aryl and arylalkyl of R2 may be further substituted with halogen, hydroxy, amino, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, 5- or 6-membered heterocycloalkyl, or 5- or 6-membered heteroaryl.]
- The hetero compound represented by
Chemical Formula 1 according to the present invention may be selected from compounds of the following structures, but is not limited thereto. - In another general aspect, there is provided a pharmaceutical composition for treating and preventing inflammatory skin diseases containing a heterocyclic compound of
Chemical Formula 1 according to the present invention or pharmaceutically acceptable salts thereof. - The inflammatory skin disease may include a skin disease with inflammation and may include acne, rosacea, seborrheic dermatitis, atopic dermatitis, post-inflammatory hyper-pigmentation (PIH), contact dermatitis, pruritus, psoriasis, Lichen planus, eczema, skin infections, Netherton Syndrome, or the like.
- In addition, there is provided a pharmaceutical composition for skin wound healing containing a heterocyclic compound of
Chemical Formula 1 according to the present invention or pharmaceutically acceptable salts thereof. - The skin wound may include a cut, a stab, an abrasion, a laceration, a bite wound, or the like, but is not limited thereto.
- In another general aspect, there is provided a pharmaceutical composition for treating and preventing metastasis of cancer, gastrointestinal disease, asthma, or hepatic cirrhosis containing a heterocyclic compound of
Chemical Formula 1 or pharmaceutically acceptable salts thereof according to the present invention. - In addition, there is provided a protease activated receptor-2 (PAR-2) inhibitor composition containing a heterocyclic compound of
Chemical Formula 1 according to the present invention or pharmaceutically acceptable salts thereof. - In addition, there is provided a cosmetic composition containing a heterocyclic compound of
Chemical Formula 1 according to the present invention. - A compound of
Chemical Formula 1, or salts thereof according to the present invention may have a PAR-2 inhibitory activity. It is known that the PAR-2 plays important roles mainly in diseases such as inflammation, cardiovascular diseases, cancer, particularly, metastasis of cancer, gastrointestinal disease such as inflammatory bowel disease (IBD), and the like, asthma, hepatic cirrhosis, or the like. Since the diseases in association with PAR-2 are mostly intractable chronic diseases as described above, the development of an effective PAR-2 inhibitor may be expected to have a large commercial potential. - It was known that particularly, in the skin, the PAR-2 is involved in an important response such as intracellular hyper-pigmentation, induction of pruritus, and the like, as well as inflammation. In addition, it was reported that the PAR-2 plays important roles in maintenance of a skin barrier function, wound healing, and the like. Therefore, the PAR-2 inhibitor is likely to effectively treat skin diseases. In the case of atopic dermatitis in which various skin symptoms are shown at the same time, since in the atopic dermatitis, which is an intractable chronic inflammatory skin disease, various symptoms such as severe pruritus, skin barrier damage, inflammation post-inflammatory hyper-pigmentation (PIH), and the like, that may be expressed by activation of PAR-2 are shown at the same time, the PAR-2 inhibitor may be primarily applied to the atopic disease.
- In addition, it was reported that expression of the PAR-2 in the skin wounds is increased, and in the case in which these wounds are treated with a component having the PAR-2 inhibitory activity, the wound healing is stimulated.
- Therefore, the compounds of
Chemical Formula 1 or salts thereof according to the present invention may be used in order to heal skin wounds as well as to treat and prevent inflammatory diseases such as skin inflammation, atopic dermatitis, or the like and be useful as medicine or a cosmetic composition. - Further, the compound of
Chemical Formula 1 and salts thereof according to the present invention may be useful as the PAR-2 inhibitory activity. - The above and other objects, features and advantages of the present invention will become apparent from the following description of preferred embodiments given in conjunction with the accompanying drawings, in which:
-
FIGS. 1 and 2 are profiles of a PAR-2 inhibitory activity assay specified in Experimental Example 1; -
FIGS. 3 and 4 are results of β-arrestin assay in Experimental Example 2; -
FIG. 5 is a graph showing an effect of recovering trans-epidermal water loss (TEWL) in oxazolone induced chronic dermatitis animal model; -
FIG. 6 is a graph showing an effect of recovering skin hydration in stratum cornea in the oxazolone induced chronic dermatitis animal model; and -
FIG. 7 is a graph showing an effect of decreasing a skin thickness in the oxazolone induced chronic dermatitis animal model. - Hereinafter, the present invention will be described in detail.
- The present invention provides imidazopyridine compounds represented by the following
Chemical Formula 1, which are novel heterocyclic compounds. - [In
Chemical Formula 1, - R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, (C6-C12)ar(C1-C7)alkyl, and
- R2 and R3 each are independently selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C3-C6)cycloalkyl, (C6-C10)aryl, (C6-C10)ar(C1-C7)alkyl, (C1-C7)alkylamido(C1-C7)alkyl, —NR11R12,
- R11, R12, R13, R14, and R15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl; R11 and R12, and R13 and R14 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- to 6-membered heterocyclic ring; R16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
- m is an integer of 1 to 4,
- (C6-C12)aryl of R2 and R3 and heterocyclic ring formed from R11 and R12, and R13 and R14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino, (C1-C7)alkylsulfonamido, or
- R21 and R22 each are independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 are linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.]
- In the present invention, preferable heterocyclic compounds are imidazopyridine compounds represented by the following Chemical Formulas 1a and 1b among imidazopyridine derivative compounds represented by
Chemical Formula 1. - In order to evaluate the inhibitory activity of the compounds of
Chemical Formula 1 against the PAR-2 that is known as to be associated with treatment and prevention of skin barrier damage, skin inflammation, psoriasis, Netherton Syndrome, atopic dermatitis, that are inflammatory skin diseases, in vitro and in vivo experiments were performed. As a result, it was confirmed that the compounds according to the present invention have the PAR-2 inhibitory activity in the cell. - Therefore, the present invention provides the pharmaceutical composition for treating or preventing the inflammatory skin diseases, the cosmetic composition, and the PAR-2 inhibitor composition containing the compounds of
Chemical Formula 1 or pharmaceutically acceptable salts thereof, wherein the inflammatory skin diseases includes skin barrier damage, psoriasis with skin inflammation, Netherton Syndrome, and atopic dermatitis. In addition, the present invention may provide a composition for skin wound healing using the fact that inhibition of PAR-2 expression may stimulate wound healing. - In the present invention, the composition or the PAR-inhibitor may include 0.001 to 90 weight %, more preferably, 0.001 to 50 weight % of the compounds of
Chemical Formula 1 according to the present invention as an active ingredient. - Further, the pharmaceutical composition containing the compounds of
Chemical Formula 1 or pharmaceutically acceptable salts thereof for treating or preventing the inflammatory skin diseases or for skin wound healing and the PAR-2 inhibitor composition according to the present invention may include all of the compositions that may be administered to a human for skin external application, injection, inhalation, oral administration, and the like. Particularly, a formulation that may be applied to the skin or mucosa is not particularly limited, but the composition may be formulated as a solution, emulsion, suspension, cream, ointment, gel, jelly, or spray. - The compound of
Chemical Formula 1 according to the present invention may be prepared through the pathway of the followingReaction Formula 1. - Hereinafter, the present invention will be described in detail through the following Examples and Experimental Examples, but is not limited thereto.
- 6-aminonicotinic acid methylester (500 mg, 3.29 mmol) and chloroacetone (1.83 g, 19.74 mmol) were dissolved in ethanol (15 mL), followed by refluxing and stirring for 24 hours. After removing a solvent, the resultant was diluted with water (15 mL), basified by sodium hydrogen carbonate saturated aqueous solution and then extracted three times with methylene chloride (MC, 10 mL). The organic layer was collected, dried over anhydrous magnesium sulfate, concentrated under reduce pressure, and purified by column chromatography (MC: MeOH=40:1), thereby obtaining methyl 2-methylimidazo[1,2-a]pyridine-6-carboxylate (340 mg, 54%).
- 1H NMR (600 MHz, chloroform-d1) d=8.80 (s, 1H), 7.65 (d, J=9.6 Hz, 1H), 7.45 (d, J=9.6 Hz, 1H), 7.38 (s, 1H) 113, 3.91 (s, 3H), 2.45 (s, 3H)
- The compound (340 mg, 1.79 mmol) obtained in
step 1 was dissolved in pyridine (4 mL), and 12 (681 mg, 2.68 mmol) was added thereto, followed by stirring at 50° C. for 4 hours. After water (80 mL) was added to the mixture, and the resultant material was extracted three times with MC (50 mL). The organic layer was collected, dried over anhydrous magnesium sulfate, concentrated under reduce pressure, and purified by column chromatography (MC:EA=3:1). Then, the concentrated compound was washed with n-hex (100 mL) and concentrated under reduced pressure, thereby obtaining methyl 3-iodo-2-methylimidazo[1,2-a]pyridine-6-carboxylate (470 mg, 83%). - 1H NMR (600 MHz, chloroform-d1) d=8.79 (s, 1H), 7.74 (d, J=9.6 Hz, 1H), 7.49 (d, J=9.6 Hz, 1H), 1133.96 (s, 3H), 2.50 (s, 3H)
- 3-iodo-2-methylimidazo[1,2-a]pyridine-6-carboxylic acid (202 mg, 85%) was obtained using the compound (250 mg, 0.791 mmol) obtained in
step 2 by the same method as that inPreparation step 2 of Example 2. The obtained compound was directly used in a next reaction without purification. - (3-iodo-2-methylimidazo[1,2-a]pyridin-6-yl)(piperidin-1-yl)methanone (180 mg, 73%) was obtained using the compound (202 mg, 0.669 mmol) obtained in
step 3 by the same method as that inPreparation step 3 of Example 2. - 1H NMR (600 MHz, chloroform-d1) d=8.25 (s, 1H), 7.49 (d, J=9.0 Hz, 1H), 7.21 (d, J=9.6 Hz, 1H), 3.71 (br d, 4H), 1132.50 (s, 3H), 1.71 (m, 6H)
- The compound (20 mg, 0.054 mmol) obtained in step 4, 3-methylphenylboronic acid (30.6 mg, 0.065 mmol), and tetrakis(triphenylphosphine) palladium (40 mg, 0.035 mmol) were dissolved in DME (6 mL), and then potassium carbonate aqueous solution (696 μL, 2M) was added thereto, followed by refluxing and stirring for 20 hours. After the mixture was cooled to room temperature and MC (10 ml) was added thereto, the resultant was washed with water (5 mL). The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduce pressure, and purified by column chromatography (MC:EA=3:1), thereby obtaining Compound 45 (14 mg, 77%).
- 1H NMR (600 MHz, chloroform-d1) d=8.28 (s, 1H), 7.56 (d, J=10.8 Hz, 1H), 7.46 (t, J=7.2 Hz, 1H, 7.27 (m, 3H), 7.16 (dd, J=8.4 Hz, 1.2 Hz, 1H), 3.65 (br d, 4H), 2.48 (s, 3H), 2.44 (s, 3H), 1.69 (m 6H)
- The compound (220 mg, 0.696 mmol) obtained in
step 2 of Example 1, phenylboronic acid (94 mg, 0.77 mmol), and tetrakis(triphenylphosphine) palladium (40 mg, 0.035 mmol) were dissolved in DME (6 mL), and then potassium carbonate aqueous solution (696 μL, 2M) was added thereto, followed by refluxing and stirring for 20 hours. After the mixture was cooled to room temperature and MC (10 ml) was added thereto, the resultant was washed with water (5 mL). The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduce pressure, and purified by column chromatography (MC:EA=3:1), thereby obtaining methyl 2-methyl-3-phenylimidazo[1,2-a]pyridine-6-carboxylate (80 mg, 43%). 1H NMR (600 MHz, chloroform-d1) d=8.83 (s, 1H), 7.71-7.47 (m, 7H), 113, 3.90 (s, 3H), 2.50 (s, 3H) - After the compound (80 mg, 0.30 mmol) obtained in
step 1 was dissolved in a mixture of tetrahydrofuran (2 mL) and ethanol (2 mL), lithium hydroxide (20 mg, 0.48 mmol) was added thereto, and water (1 mL) was added thereto, followed by stirring for 12 hours. The resultant was neutralized with 1N HCl and concentrated under reduced pressure, thereby obtaining 2-methyl-3-phenylimidazo[1,2-a]pyridine-6-carboxylic acid (78 mg, 98%). The obtained compound was directly used in a next reaction without purification - The compound (100 mg, 0.396 mmol) obtained in
step 2 and tert-butyl piperazine-1-carboxylate (89 mg, 0.475 mmol) were dissolved in DMF (2 mL), DIPEA (253 μL, 1.452 mmol), N-Boc piperazine (90 mg, 1.057 mmol) were sequentially added thereto. Then, PyBOP (259 mg, 498 mmol) was added thereto, followed by stirring at room temperature for 1 hour. After water (10 mL) was added to the reaction mixture, the resultant was extracted with ethylacetate (12 mL). The organic layer was washed with saturated saline (10 mL), dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and purified by column chromatography (MC:EA=1:1 to 1:2), thereby obtaining tert-butyl 4-(2-methyl-3-phenylimidazo[1,2-a]pyridine-6-carbonyl)piperazine-1-carboxylate (100 mg, 60%). - 1H NMR (600 MHz, chloroform-d1) d=8.33 (s, 1H), 7.59-7.44 (m, 6H), 7.16 (dd, J=7.2 Hz, 1.2 Hz, 1H), 3.86 (br s, 4H), 3.38 (br s, 4H), 2.53 (s, 3H)
- HCl dioxane (5 mL, 4M) was added to the compound (100 mg, 0.238 mmol) obtained in
step 3, followed by stirring at room temperature for 2 hours. The mixture was concentrated under reduced pressure, thereby obtaining (2-methyl-3-phenylimidazo[1,2-a]pyridin-6-yl)(piperazin-1-yl)methanone hydrochloride salts (108 mg, 99%). - 1H NMR (600 MHz, CD3OD-d4) d=8.62 (s, 1H), 8.02 (m, 2H), 7.69 (m, 5H), 3.59 (br s, 4H), 3.46 (br s, 4H), 2.50 (s, 3H), 1.47 (s, 9H)
- After the compound (27 mg, 0.076 mmol) obtained in step 4 was dissolved in MC (1 mL), TEA (32 μL, 0.228 mmol) was added thereto, and then cyclohexanecarbonylchloride (12 μL, 0.091 mmol) was added thereto at 0° C. Stirring was performed at 0° C. for 10 minutes and again at room temperature for 30 minute, and then methanol (0.1 mL) was added thereto. The resultant was concentrated under reduce pressure, and purified by column chromatography (MC: MeOH=40:1), thereby obtaining Compound 73 (26 mg, 79%).
- 1H NMR (600 MHz, chloroform-d1) d=8.34 (s, 1H), 7.59˜7.45 (m, 6H), 7.16 (dd, J=9.0 Hz, 1.2 Hz, 1H), 3.63 (br d, 8H), 2.47 (s, 3H), 1.90-1.24 (m 11H)
- In order to evaluate the PAR-2 inhibitory effect of
Compounds - In order to evaluate inhibitory activity of the synthesized materials against the PAR-2, primarily, an assay system in which a concentration of calcium ions in cell may be measured in real time was constructed, and evaluation was conducted using this system. The PAR-2 is a kind of G-protein coupled receptors (GPCR), and when the PAR-2 is activated in cell, phospholipase C-b (PLC-b) decomposes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacyl glycerol (DAG) while being activated. IP3 generated at this time stimulates secretion of calcium ions in endoplasmic reticulum (ER), which is a storage of calcium ions in a cell, such that the concentration of calcium ions in the cell is increased. Based on an existing study result, an in vitro screening assay system capable of detecting a material capable of suppressing the concentration of calcium ions in the cell from being increased by activation of PAR-2 was constructed. As a PAR-2 activating agent, activating peptide (AP) was used, and as a reagent for detecting the concentration of calcium ion in the cell, a Calcium-4 assay kit produced (Molecular Probe). As a cell line used in experiments, HCT-15 in which PAR-2 is over-expressed was used. Inhibitor candidates were treated for 5 minutes and then treated with AP, a change in fluorescence was observed for 2 minutes in real time using a FlexStation II (Molecular Device Corp.).
- The inhibitory activity of the synthesized materials against the PAR-2 was evaluated using the protocol as described above, and profiles of the assay for
Compounds FIGS. 1 and 2 . - β-Arrestin GPCR Assay
- An in vitro assay protocol capable of detecting activation of the PAR-2 was additionally introduced in addition to a calcium immobilization assay to measure the activity of the selected materials. First, the PAR-2 inhibitory activities of two kinds of samples were measured using a PathHunter™ β-arrestin GPCR assay kit (DiscoveRx Corp.) capable of detecting accumulation of β-arrestin, which is an intracellular reaction firstly generated by the activation of the PAR-2. Experiments were conducted by diluting concentrations of the samples by one-half, ranging from 1000 to 50 μM and SKIGKV-NH2 (10 μM) was treated with the PAR-2 inhibitor. As an experimental result, suppression of β-arrestin was confirmed in both of the two kinds of samples at a concentration of 500 μM. As a measurement result, it was observed that IC50 values were different from those in calcium immobilization assay (See Table 1).
-
TABLE 1 Result comparison of Calcium-4 assay and β-arrestin assay IC50 (μM) Compound Calcium-4 PathHunter ™ CC50 (μM) Compound 4573.79 338.56 >100 Compound 7376.68 400.78 >100 - In order to visually confirm the activation of the PAR-2, a cell line having the following structure was prepared based on existing references, and activation of the PAR-2 was observed using a confocal microscope. As the cell line, Kirsten Murine Sarcoma Virus transformed rat kidney epithelial cell (KNRK cell) was used. In this cell line, the PAR-2 may not be expressed in a normal state. Each of the N-terminals of KNRK cell were tagged with Flag epitope, and each of the C-terminals were tagged with Myc epitope, such that a stable transfected cell was constructed. Each of Flag and Myc with respect to the KNRK-PAR-2 cell line prepared as described above was double-stained, and whether or not the PAR-2 was activated was observed using the confocal microscope ([trypsin]=1 μM, [SLIGKV(AP)]=100 μM). In a state in which the PAR-2 was not activated, Flag and Myc were double stained, such that a yellow image was shown in a merged image. However, in the case in which the PAR-2 was activated, a red image was shown while the Flag is separated.
- In the case in which the KNRK-PAR-2 cell line was simultaneously treated with trypsin, activating peptide (SLIGKV), and the selected inhibitor material, Compound 45 ([trypsin]=11 μM, [SLIGKV (activating peptide)]=100 μM, [Compound 45]=200 μM), it was observed that a yellowish image was shown, such that it was confirmed that activation of the PAR-2 was suppressed.
- Effects of the selected materials were evaluated using chronic dermatitis animal model. Oxazolone induced chronic dermatitis animal model by continuously applying oxazolone, which is a kind of hapten, to a hairless mouse was used. It was reported that various symptoms of atopic dermatitis relatively accurately appear in recently developed oxazolone model, and the present inventors also confirmed through the prior study that various symptoms of general atopic dermatitis appear similarly to clinically appearing symptoms. In order to construct the chronic dermatitis animal model, 5% oxazolone was applied and sensitized to the hairless mice (SKH-1, 6 weeks old). After 1 week, 0.1% oxazolone was applied every other day for 2 weeks, thereby induced the symptoms of dermatitis. After samples were applied to the dermatitis induced animal once a day for 3 days, changes in various skin functions and a skin thickness were observed. Finally, biopsy was performed on skin tissue, and histological observation was conducted.
- As a positive control group used in the experiment, 0.05% desonide formulation, which is a steroid having relatively weak potency, was used, and changes in trans-epidermal water loss (TEWL) skin hydration in stratum cornea, and skin thickness were observed. As shown in
FIGS. 5 to 7 , it was observed thatCompound 45 may effectively restore trans-epidermal water loss (TEWL) and skin hydration in stratum cornea and reduce the skin thickness. Particularly,Compound 45 has statistically significant improvement effect on the skin thickness.
Claims (11)
1. Heterocyclic compounds represented by the following Chemical Formula 1.
[In Chemical Formula 1,
R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, (C6-C12)ar(C1-C7)alkyl, and
R2 and R3 each are independently selected from hydrogen, halogen, (C1-C7)alkyl, amino, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C3-C6)cycloalkyl, (C6-C10)aryl, (C6-C10)ar(C1-C7)alkyl, (C1-C7)alkylamido(C1-C7)alkyl, —NR11R12,
R11, R12, R13, R14, and R15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl; R11 and R12, and R13 and R14 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- to 6-membered heterocyclic ring; R16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
m is an integer of 1 to 4; and
(C6-C12)aryl of R2 and R3 and heterocyclic ring formed from R11 and R12 and R13 and R14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino, (C1-C7)alkylamido, (C1-C7)alkylcarbamoyl, (C1-C7)alkylsulfonamido, or
R21 and R22 each are independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 are linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.]
2. The Heterocyclic compounds of claim 1 , wherein it is represented by the following Chemical Formula 2.
[In Chemical Formula 2,
R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, and
R4 is selected from hydrogen, halogen, (C1-C7)alkyl, (C1-C7)alkoxy, (C1-C7)alkoxycarbonyl, (C6-C10)aryl, (C1-C7)alkylamido(C1-C7)alkyl, —NR11R12,
R11, R12, R13, R14, and R15 each are independently selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, and heteroaryl; R11 and R12, and R13 and R14 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- to 6-membered heterocyclic ring; R16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)aryl;
(C6-C12)aryl of R2 and R4 and heterocyclic ring formed from R11 and R12, and R13 and R14 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino(C1-C7)alkylamido(C1-C7)alkylcarbamoyl, (C1-C7)alkylsulfonamido, or
R21 and R22 each are independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 are linked to each other via alkylene to form 5- or 6-membered heterocyclic ring;
R5 is independently selected from halogen and (C1-C7)alkyl; and
n is an integer of 1 to 3.]
3. The heterocyclic compounds of claim 1 , wherein it is represented by the following Chemical Formula 3.
[In Chemical Formula 3,
R1 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-12)aryl, and
R6 is —NR11R12; R11 and R12 each are independently hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C6-C10)aryl, heterocycloalkyl(C6-C12)aryl, heteroaryl, R11 and R12 are linked to each other via alkylene, oxyalkylene, or aminoalkylene to form a 5- or 6-membered heterocyclic ring; R16 is selected from hydrogen, (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C10)ary; and
(C6-C12)aryl of R2 and R6 and heterocyclic ring formed from R11 and R12 may be further substituted with halogen, hydroxyl, (C1-C7)alkyl, (C3-C6)cycloalkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocycloalkylcarbonyl, (C6-C10)aryl(C6-C10)arylcarbonyl, (C1-C6)alkoxy, (C1-C7)alkoxycarbonyl, (C1-C7)alkylcarbonyl, (C3-C6)cyclo(C1-C7)alkylcarbonyl, (C6-C10)ar(C1-C7)alkylcarbonyl, (C3-C6)heteroarylcarbonyl, 5- or 6-membered cycloalkylsulfonyl, (C1-C7)alkylsulfonyl, amino(C1-C7)alkylcarbonyl, (C1-C7)alkyloxycarbonyl, (C6-C10)ar(C1-C7)alkyloxycarbonyl, amino, (C1-C7)alkylamino, (C1-C7)alkylamido, (C1-C7)alkylcarbamoyl, (C1-C7)alkylsulfonamido, or
R21 and R22 each are independently (C1-C7)alkyl, (C3-C6)cycloalkyl, or (C6-C12)ary, or R21 and R22 are linked to each other via alkylene to form 5- or 6-membered heterocyclic ring.]
4. The heterocyclic compounds of claim 1 , wherein it is represented by the following Chemical Formula 4.
[In Chemical Formula 4,
R2 is amino, (C6-C10)aryl, or (C6-C10)ar(C1-C7)alkyl;
A is —CH2 or —NR31; R31 is selected from hydrogen, (C1-C7)alkyl, (C1-C7)alkylcarbonyl, and (C3-C6)cycloalkylcarbonyl; and aryl and arylalkyl of R2 may be further substituted with halogen, hydroxy, amino, (C1-C7)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, 5- or 6-membered heterocycloalkyl, or 5- or 6-membered heteroaryl.]
6. A pharmaceutical composition for treating and preventing inflammatory skin diseases comprising the heterocyclic compound of Chemical Formula 1 of claim 1 or pharmaceutically acceptable salts thereof.
7. The pharmaceutical composition for treating and preventing inflammatory skin diseases of claim 6 , wherein the inflammatory skin disease includes a skin disease with inflammation and may include acne, rosacea, seborrheic dermatitis, atopic dermatitis, post-inflammatory hyper-pigmentation (PIH), contact dermatitis, pruritus, psoriasis, Lichen planus, eczema, skin infections, Netherton Syndrome, or the like.
8. A pharmaceutical composition for skin wound healing comprising the heterocyclic compound of Chemical Formula 1 of claim 1 or pharmaceutically acceptable salts thereof.
9. A pharmaceutical composition for treating and preventing metastasis of cancer, gastrointestinal disease, asthma, or hepatic cirrhosis comprising the heterocyclic compound of Chemical Formula 1 of claim 1 or pharmaceutically acceptable salts thereof.
10. A protease activated receptor-2 (PAR-2) inhibitor composition comprising the heterocyclic compound of Chemical Formula 1 of claim 1 or pharmaceutically acceptable salts thereof.
11. A cosmetic composition comprising the heterocyclic compound represented by Chemical Formula 1 of claim 1 .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100082258 | 2010-08-25 | ||
KR10-2010-0082258 | 2010-08-25 | ||
PCT/KR2011/006278 WO2012026765A2 (en) | 2010-08-25 | 2011-08-25 | Novel heterocyclic compound, and composition for treating inflammatory diseases using same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130165652A1 true US20130165652A1 (en) | 2013-06-27 |
Family
ID=45723936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/818,420 Abandoned US20130165652A1 (en) | 2010-08-25 | 2011-08-25 | Novel heterocyclic compound, and composition for treating inflammatory diseases using same |
US13/818,355 Expired - Fee Related US8809541B2 (en) | 2010-08-25 | 2011-08-25 | Heterocyclic compound, and composition for treating inflammatory diseases using same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/818,355 Expired - Fee Related US8809541B2 (en) | 2010-08-25 | 2011-08-25 | Heterocyclic compound, and composition for treating inflammatory diseases using same |
Country Status (9)
Country | Link |
---|---|
US (2) | US20130165652A1 (en) |
EP (2) | EP2617721A4 (en) |
JP (1) | JP5894161B2 (en) |
KR (2) | KR20130059400A (en) |
CN (1) | CN103119042B (en) |
DK (1) | DK2610255T3 (en) |
ES (1) | ES2573148T3 (en) |
PL (1) | PL2610255T3 (en) |
WO (2) | WO2012026766A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10030024B2 (en) | 2013-09-25 | 2018-07-24 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway |
US11529359B2 (en) | 2016-01-27 | 2022-12-20 | Universitat Zurich | Use of GABAA receptor modulators for treatment of itch |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34305A (en) | 2011-09-01 | 2013-04-30 | Novartis Ag | DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
WO2014009295A1 (en) | 2012-07-13 | 2014-01-16 | Ucb Pharma S.A. | Imidazopyridine derivatives as modulators of tnf activity |
KR101421032B1 (en) | 2012-12-28 | 2014-07-22 | 주식회사 레고켐 바이오사이언스 | Method for preparing (2-methyl-1-(3-methylbenzyl)-1H-benzo[d]imidazol-5-yl)(piperidin-1-yl)methanone |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN103113306A (en) * | 2013-03-07 | 2013-05-22 | 同济大学 | Synthesis method of 2,3-benzopyrrole compound NPS-1577 |
US10369121B2 (en) | 2013-08-23 | 2019-08-06 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient |
KR102100244B1 (en) | 2013-12-19 | 2020-04-13 | 에스케이이노베이션 주식회사 | Electrolyte for Lithium Secondary Battery and Lithium Secondary Battery Containing the Same |
ES2702337T3 (en) | 2014-04-29 | 2019-02-28 | Catholic Univ Korea Ind Academic Cooperation Foundation | Compound that has a therapeutic effect in immune diseases and use thereof |
WO2018057588A1 (en) * | 2016-09-21 | 2018-03-29 | Vertex Pharmaceuticals Incorporated | Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway |
JOP20190086A1 (en) | 2016-10-21 | 2019-04-18 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
JP7263538B2 (en) * | 2019-11-01 | 2023-04-24 | 株式会社 資生堂 | Skin condition evaluation method using active PAR-2 in skin as index, screening method for PAR-2 activation promoter or inhibitor, and PAR-2 activation inhibitor |
KR102394110B1 (en) | 2020-01-22 | 2022-05-04 | 가톨릭대학교 산학협력단 | Novel compound and uses of the same |
CA3197751A1 (en) | 2020-10-06 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Autotaxin inhibitor compounds |
US20240066027A1 (en) | 2020-12-03 | 2024-02-29 | Domain Therapeutics | Novel par-2 inhibitors |
KR20240035820A (en) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Aryl compounds and pharmaceutical compositions that modulate IKZF2 |
KR102323657B1 (en) | 2021-10-06 | 2021-11-09 | (주)네오팜 | Composition for anti-inflammatory |
WO2023233033A1 (en) | 2022-06-03 | 2023-12-07 | Domain Therapeutics | Novel par-2 inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4962100A (en) * | 1985-04-17 | 1990-10-09 | Takeda Chemical Industries, Ltd. | 3-Condensed imidazolium-cephem compounds |
US4988698A (en) * | 1988-11-21 | 1991-01-29 | Fujisawa Pharmaceutical Co., Ltd. | 2(1H)-quinolinone compounds and pharmaceutical composition comprising the same |
US7125888B2 (en) * | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US8524756B2 (en) * | 2004-09-21 | 2013-09-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE620141A (en) * | ||||
US6130235A (en) * | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
CN1229351C (en) * | 1998-05-22 | 2005-11-30 | 西奥斯股份有限公司 | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
US6348032B1 (en) * | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
US6274937B1 (en) * | 1999-02-01 | 2001-08-14 | Micron Technology, Inc. | Silicon multi-chip module packaging with integrated passive components and method of making |
SE0003186D0 (en) * | 2000-09-07 | 2000-09-07 | Astrazeneca Ab | New process |
US20040002524A1 (en) | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
JP2004170323A (en) | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | Screening method for cutaneous disease therapeutic agent |
JP2009001495A (en) | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | 2-aryl-benzimidazole-5-carboxamide derivative |
KR20080094962A (en) * | 2006-02-20 | 2008-10-27 | 아스텔라스세이야쿠 가부시키가이샤 | Amide derivative or salt thereof |
FR2903107B1 (en) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
US7723164B2 (en) * | 2006-09-01 | 2010-05-25 | Intel Corporation | Dual heat spreader panel assembly method for bumpless die-attach packages, packages containing same, and systems containing same |
US8039309B2 (en) * | 2007-05-10 | 2011-10-18 | Texas Instruments Incorporated | Systems and methods for post-circuitization assembly |
CN101687815A (en) * | 2007-06-26 | 2010-03-31 | 塞诺菲-安万特股份有限公司 | The regioselective copper catalyzed of benzoglyoxaline and azepine benzoglyoxaline synthesized |
GB0800035D0 (en) * | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
FR2925902B1 (en) * | 2008-01-02 | 2011-01-07 | Sanofi Aventis | IMIDAZO-1,2-α-PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
US7741194B2 (en) * | 2008-01-04 | 2010-06-22 | Freescale Semiconductor, Inc. | Removable layer manufacturing method |
WO2009119776A1 (en) * | 2008-03-27 | 2009-10-01 | 武田薬品工業株式会社 | Fused heterocyclic derivative and use thereof |
WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
ES2403633T3 (en) * | 2008-12-04 | 2013-05-20 | Proximagen Limited | Imidazopyridine Compounds |
-
2011
- 2011-08-25 WO PCT/KR2011/006281 patent/WO2012026766A2/en active Application Filing
- 2011-08-25 EP EP11820192.0A patent/EP2617721A4/en not_active Withdrawn
- 2011-08-25 DK DK11820193.8T patent/DK2610255T3/en active
- 2011-08-25 EP EP11820193.8A patent/EP2610255B1/en active Active
- 2011-08-25 KR KR1020137004612A patent/KR20130059400A/en active IP Right Grant
- 2011-08-25 ES ES11820193.8T patent/ES2573148T3/en active Active
- 2011-08-25 CN CN201180041194.4A patent/CN103119042B/en active Active
- 2011-08-25 KR KR1020137004500A patent/KR101477156B1/en active IP Right Grant
- 2011-08-25 JP JP2013525831A patent/JP5894161B2/en not_active Expired - Fee Related
- 2011-08-25 US US13/818,420 patent/US20130165652A1/en not_active Abandoned
- 2011-08-25 US US13/818,355 patent/US8809541B2/en not_active Expired - Fee Related
- 2011-08-25 PL PL11820193T patent/PL2610255T3/en unknown
- 2011-08-25 WO PCT/KR2011/006278 patent/WO2012026765A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4962100A (en) * | 1985-04-17 | 1990-10-09 | Takeda Chemical Industries, Ltd. | 3-Condensed imidazolium-cephem compounds |
US4988698A (en) * | 1988-11-21 | 1991-01-29 | Fujisawa Pharmaceutical Co., Ltd. | 2(1H)-quinolinone compounds and pharmaceutical composition comprising the same |
US7125888B2 (en) * | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US8524756B2 (en) * | 2004-09-21 | 2013-09-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Non-Patent Citations (4)
Title |
---|
Adams, R. J. Amer. Chem. Soc. 1954 vol 76, pp. 1845-47 * |
Bienayme, H. et al, Angew Chem IEE 1998 vol 37, pp. 2234-2237 * |
CAPLUS 1963:450748 * |
CAPLUS 2005:1310699 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10030024B2 (en) | 2013-09-25 | 2018-07-24 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway |
US11529359B2 (en) | 2016-01-27 | 2022-12-20 | Universitat Zurich | Use of GABAA receptor modulators for treatment of itch |
Also Published As
Publication number | Publication date |
---|---|
US8809541B2 (en) | 2014-08-19 |
KR20130069737A (en) | 2013-06-26 |
WO2012026766A3 (en) | 2012-06-07 |
WO2012026765A2 (en) | 2012-03-01 |
EP2617721A2 (en) | 2013-07-24 |
CN103119042B (en) | 2016-06-01 |
KR20130059400A (en) | 2013-06-05 |
EP2610255B1 (en) | 2016-02-24 |
EP2610255A2 (en) | 2013-07-03 |
JP5894161B2 (en) | 2016-03-23 |
WO2012026766A2 (en) | 2012-03-01 |
EP2610255A4 (en) | 2014-02-12 |
PL2610255T3 (en) | 2016-08-31 |
EP2617721A4 (en) | 2014-01-08 |
KR101477156B1 (en) | 2014-12-29 |
DK2610255T3 (en) | 2016-05-30 |
JP2013538209A (en) | 2013-10-10 |
ES2573148T3 (en) | 2016-06-06 |
WO2012026765A3 (en) | 2012-06-07 |
CN103119042A (en) | 2013-05-22 |
US20130158047A1 (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130165652A1 (en) | Novel heterocyclic compound, and composition for treating inflammatory diseases using same | |
US20210023043A1 (en) | Methods of Treating Hyperalgesia | |
DE69728585T2 (en) | Antipruritic agent | |
JP4205430B2 (en) | Condensed pyridine derivatives for use as vanilloid receptor antagonists to treat pain | |
KR101456994B1 (en) | Androgen receptor antagonists and uses thereof | |
CA2829322C (en) | Substituted thioimidazolidinone androgen receptor antagonists and uses thereof | |
WO2018027892A1 (en) | Amino pyrimidine ssao inhibitors | |
RU2767051C2 (en) | High-penetration prodrug compositions based on peptides and peptide-related compounds | |
JP2017523193A (en) | Compounds active against nuclear receptors | |
AU2017319080B2 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
US20220298176A1 (en) | Heteroaryl plasma kallikrein inhibitors | |
US20240083877A1 (en) | Novel scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | |
Failli et al. | Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists | |
US8362028B2 (en) | Pseudobase benzo[c]phenanthridines with improved efficacy, stability and safety | |
CN101835747A (en) | Benzimidazole derivative | |
Lima et al. | Antispasmodic and myorelaxant effects of the flavoring agent methyl cinnamate in gut: Potential inhibition of tyrosine kinase | |
KR20200034723A (en) | New spirolactone compounds | |
US20220401435A1 (en) | Mrgprx2 antagonist for the treatment of pseudo allergic reactions | |
EP1994931A1 (en) | Prophylactic or therapeutic agent for allergic ophthalmic disease or allergic nasal disease comprising tricyclic triazolobenzoazepine derivative | |
AU2014261899A1 (en) | Pharmaceutical use of hexahydro-dibenzo[a,g]quinolizine compounds | |
JP2021516259A (en) | Compositions and Methods for Treating Cutaneous Fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEOPHARM CO.,LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GWAK, HYUNG SUB;KIM, YONG ZU;KIM, UK IL;AND OTHERS;REEL/FRAME:029952/0543 Effective date: 20130222 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |